<DOC>
	<DOCNO>NCT02660840</DOCNO>
	<brief_summary>To establish bioequivalence new film-coated tablet formulation 0.5 mg , 1 mg 5 mg flupentixol market coated tablet formulation 0.5 mg , 1 mg , 5 mg flupentixol , administer single dos</brief_summary>
	<brief_title>Comparative Study Pharmacokinetics Bioequivalence Two Flupentixol Formulations</brief_title>
	<detailed_description>All subject confine clinic Day -1 ( Baseline ) Day 6 ( 120 hour post-dose ) dose period . First second dosing separate washout period least 21 day</detailed_description>
	<mesh_term>Flupenthixol</mesh_term>
	<mesh_term>Flupenthixol decanoate</mesh_term>
	<criteria>body mass index ( BMI ) ≥18.5 ≤30 kg/m2 The subject , opinion investigator , generally healthy base medical history , physical examination , vital sign , electrocardiogram ( ECG ) , result haematology , clinical chemistry , urinalysis , serology , laboratory test . The subject pregnant breastfeeding . The subject take investigational medicinal product 3 month prior first dose The subject test positive Screening Visit Baseline Visit drug abuse ( opiate , methadone , cocaine , amphetamine [ include ecstasy ] , barbiturate , benzodiazepine , cannabinoids ) . Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>